# BioticsAI Navigates FDA Approval and Healthcare's Regulatory Gauntlet
Robhy Bustami built BioticsAI to solve a problem most startups avoid. Healthcare regulation kills momentum. Most founders burn out before their first FDA approval.
Bustami didn't. The company recently crossed that regulatory finish line while maintaining team morale through the grueling process. He joined Build Mode to break down how.
FDA approval in healthcare requires patience that venture capital rarely rewards. Bustami kept his team focused by reframing timelines. Regulatory delays aren't failures. They're checkpoints. This mindset shift separated BioticsAI from startups that collapse under pressure.
The market opportunity here is substantial. Healthcare systems waste billions on inefficient processes. BioticsAI targets that gap with AI tools built to pass regulatory scrutiny from day one, not after launch.
Fundraising while navigating FDA requirements demands a different pitch. Most VCs want growth metrics immediately. Healthcare investors understand that approval timelines matter more than early traction. Bustami learned to speak each language.
The startup's survival hinges on this core insight: regulation isn't a bug in healthcare, it's the feature. Winners build compliance into their DNA instead of bolting it on later. BioticsAI structured itself that way from the beginning.